Digestive Diseases, Hospital Universitario Virgen de Rocío, España.
Digestive Diseases, University Hospital Virgen del Rocío.
Rev Esp Enferm Dig. 2022 May;114(5):280-288. doi: 10.17235/reed.2021.8139/2021.
hepatitis B virus (HBV) is the main risk factor for hepatocellular carcinoma (HCC). We performed a meta-analysis based on Asian data to evaluate the diagnostic accuracy of circulating microRNA as a non-invasive biomarker in the diagnosis of HBV-related HCC.
a comprehensive literature search (updated to May 12, 2021) in PubMed, Embase, Web of Science, Wanfang Database, and China National Knowledge Infrastructure (CNKI) was performed to identify eligible studies. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) for diagnosing HBV-related HCC were pooled in this meta-analysis. A subgroup analysis was performed to explore heterogeneity, and Deeks' funnel plot was used to assess publication bias.
a total of 19 articles including 32 studies were included in the current meta-analysis. The overall sensitivity, specificity, PLR, NLR, DOR and AUC were 0.83 (95 % CI: 0.79 to 0.87), 0.78 (95 % CI: 0.73 to 0.83), 3.9 (95 % CI: 3.0 to 4.9), 0.21 (95 % CI: 0.16 to 0.27), 18 (95 % CI: 12 to 27) and 0.88 (95 % CI: 0.85 to 0.91), respectively. Subgroup analysis shows that miRNA clusters with a large sample size showed better diagnostic accuracy. Although there is no publication bias, the research still has some limitations.
circulating miRNAs could serve as a potential non-invasive biomarker in diagnosing HBV-related HCC in Asian populations.
乙型肝炎病毒（HBV）是肝细胞癌（HCC）的主要危险因素。我们基于亚洲数据进行了一项荟萃分析，以评估循环 microRNA 作为一种非侵入性生物标志物在诊断 HBV 相关 HCC 中的诊断准确性。
在 PubMed、Embase、Web of Science、万方数据库和中国知网（CNKI）中进行了全面的文献检索（更新至 2021 年 5 月 12 日），以确定合格的研究。在荟萃分析中汇总了用于诊断 HBV 相关 HCC 的灵敏度、特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）和曲线下面积（AUC）。进行了亚组分析以探索异质性，并使用 Deeks 漏斗图评估发表偏倚。
共有 19 篇文章（共 32 项研究）纳入了本次荟萃分析。总体灵敏度、特异性、PLR、NLR、DOR 和 AUC 分别为 0.83（95%置信区间：0.79 至 0.87）、0.78（95%置信区间：0.73 至 0.83）、3.9（95%置信区间：3.0 至 4.9）、0.21（95%置信区间：0.16 至 0.27）、18（95%置信区间：12 至 27）和 0.88（95%置信区间：0.85 至 0.91）。亚组分析显示，样本量大的 miRNA 簇具有更好的诊断准确性。尽管没有发表偏倚，但该研究仍存在一些局限性。
循环 microRNA 可作为亚洲人群诊断 HBV 相关 HCC 的一种潜在非侵入性生物标志物。
